Clinical trials: sponsored by OHSU Knight Cancer Institute
- Lead sponsor (exact) OHSU Knight Cancer Institute
- Age group Children (under 18)
- Has posted results yes
Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ
Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Thrombocytopenia
- Trial name
- NCT00074165
- Testing
- Rituxan, Cyclophosphamide, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- OHSU Knight Cancer Institute
Brain Neoplasms
Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation
Combidex (ferumoxtran-10) is an ultra-small iron oxide particle covered with a sugar coating. It has been evaluated as an MRI contrast agent for use in imaging well perfused organs such as the liver and spleen and for imaging…
- Trial name
- NCT00659334
- Testing
- Ferumoxtran-10 (Combidex), Neurosurgery
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- OHSU Knight Cancer Institute
Sarcoma
Progressive Resistance Training for the Improvement of Physical Function
This trial studies how well progressive resistance training works in improving the physical function of sarcoma survivors. Treatments for sarcoma can cause side effects such as fatigue, muscle loss, and weakness, which can…
- Trial name
- NCT04247425
- Testing
- Exercise Counseling, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- OHSU Knight Cancer Institute
Childhood Brain Neoplasm, Recurrent Childhood Brain Neoplasm
DSC-MRI With Ferumoxytol and DCE-MRI With Gadolinium in Imaging Vascular Properties in Younger Patients With Brain Tumors
This clinical trial studies dynamic susceptibility-weighted contrast enhanced magnetic resonance imaging (DSC-MRI) after administration of ferumoxytol and dynamic contrast-enhanced MRI (DCE-MRI) after administration of a…
- Trial name
- NCT00978562
- Testing
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol Non-Stoichiometric Magnetite
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- OHSU Knight Cancer Institute
Health Status Unknown, Prostate Carcinoma
Transrectal MRI-Guided Biopsy in Identifying Cancer in Patients With Suspected Prostate Cancer
This pilot clinical trial studies transrectal magnetic resonance imaging (MRI)-guided biopsy to see how well it works in identifying cancer in patients with suspected prostate cancer who are scheduled to undergo standard biopsy.
- Trial name
- NCT02501759
- Testing
- 3 Tesla Magnetic Resonance Imaging, Gadodiamide, Multiparametric Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
Lymphoma
Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma
RATIONALE: Chemotherapy, such as busulfan, melphalan, and thiotepa, may destroy cancerous blood-forming cells (stem cells) in the blood and bone marrow.
- Trial name
- NCT00238433
- Testing
- filgrastim, busulfan, melphalan
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- OHSU Knight Cancer Institute
Leukemia
Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and total-body irradiation (TBI) before a donor stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00416884
- Testing
- Campath, Fludarabine, Total Body Irradiation (TBI)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- OHSU Knight Cancer Institute
Chronic Myeloproliferative Disorders, Leukemia
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
RATIONALE: A peripheral stem cell transplant or an umbilical cord blood transplant from a donor may be able to replace blood-forming cells that were destroyed by chemotherapy or radiation therapy.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00281879
- Testing
- anti-thymocyte globulin, filgrastim, busulfan
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- OHSU Knight Cancer Institute
Leukemia, Myelodysplastic Syndromes
Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy, such as treosulfan and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00253513
- Testing
- fludarabine, treosulfan, allogeneic blood or bone marrow transplantation
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- OHSU Knight Cancer Institute